Measuring the efficiency of a solids-based wastewater extraction using BCoV and validation of a BCoV and PMMoV RT-qPCR duplex assay Authors: Codey E Dueck, Nataliya Santiago, Nikho A Hizon, Ravinder Lidder, Dave Spreitzer, Umar P Mohammed, MacKenzie Dyck, Chand S Mangat, Edgard M Mejia Published: 2026 ABSTRACT AbstractBovine coronavirus (BCoV) is commonly used to evaluate the efficiency of nucleic acid extraction protocols used in wastewater-based surveillance (WBS). Here we outline a method for measuring the efficiency of a solids-based extraction protocol using RT-qPCR detections of BCoV spiked into wastewater samples. Validation steps included: determination of a suitable quantification method for BCoV starting material, measures of endogenous BCoV in wastewater, assessment of the effects of BCoV incubation times on wastewater extraction efficiencies, and implementation of a BCoV and Pepper Mild Mottle Virus (PMMoV) RT-qPCR duplex assay. Results show that an accurate baseline measure of BCoV stock concentrations is best achieved using heat lysis extraction compared to an automated method. We also show that endogenous BCoV can be present in wastewater, albeit at low viral loads. Additionally, a BCoV incubation time of 16 h in wastewater resulted in the highest percent recovery. Lastly, the use of the BCoV and PMMoV RT-qPCR duplex assay demonstrates comparable performance to their singleplex counterparts.• A method for measuring the extraction efficiency of a solids-based wastewater extraction process using BCoV.• Insights into the in situ prevalence of BCoV in wastewater samples.• Assessment of a multiplex assay for simultaneous detection of BCoV and PMMoV.Keywords: Nucleic acid extraction, Wastewater-based surveillance, Surrogate recovery control, Quality control, Endogenous control Specifications table Subject areaEnvironmental ScienceMore specific subject areaWastewater-Based SurveillanceName of your methodNML wastewater solids-based extraction efficiency measureName and reference of original methodn/aResource availability• BOVILIS® CORONAVIRUS (Merck Animal Health, Catalog #156332)• 5 mL BD Luer-Lok™ Syringe (BD; 309646)• Omni International™ Bead Ruptor Elite™ Bead Mill Homogenizer (Fisher Scientific, Catalog #17-100-864)• MagNA Pure 96 DNA and Viral NA Large Volume Kit (Roche, Catalog #06 374 891 001)• QuantStudio™ 5 Real-Time PCR System, 96-well, 0.2 mL (Applied Biosystems, Catalog #A28574)• Ambion® Carrier RNA (1 mg/mL) (Applied Biosystems, Catalog # 4382878)• BioSpec Zirconia/Silica Beads (0.5 mm dia) (BioSpec, Catalog #11079105z)• Buffer RLT (Qiagen, Catalog #79216)• 2-Mercaptoethanol (Merck MilliporeSigma (Sigma-Aldrich))• Custom DNA Oligos (IDT)• QuantStudio™ Absolute Q™ Digital PCR System, desktop (Applied Biosystems, Catalog #A52864)• Absolute Q MAP16 Plate Kit (Applied Biosystems, Catalog #A52865)• Absolute Q™ 1-step RT-dPCR Master Mix (4X) (Applied Biosystems, Catalog #A55146)• Absolute Q™ DNA Digital PCR Master Mix (5X) (Applied Biosystems, Catalog #A52490)• 1X TE buffer pH 7.5 (IDT, Catalog #11-05-01-05) Background Wastewater-based surveillance (WBS) allows for the monitoring of a myriad of biological and chemical targets at a community level. However, data interpretability can be hindered by technical constraints associated with a lack of standardized methods [1]. The inclusion of a process control in wastewater extractions is highly recommended to help capture variabilities from any given sample and individual processing runs [2,3]. Here, we provide a method describing the use of bovine coronavirus (BCoV) for measuring the wastewater extraction efficiency of a solids-based protocol isolating viral nucleic acids. Previous studies have shown the use of different surrogate viruses as process controls to measure extraction efficiency, including: BCoV [4], bovine respiratory syncytial virus (BRSV) [5], and murine hepatitis virus (MHV) [6]. Limitations of viral process controls include morphological differences between surrogate viruses, type of wastewater extraction method, and the fraction of the wastewater used for extraction (e.g., sludge, liquid, or solid). The Public Health Agency of Canada’s National Microbiology Laboratory makes use of a solids-based extraction process for its WBS program [7,8] as this method has afforded greater sensitivity compared to others [6,[9], [10], [11]]. We show the incorporation of BCoV into this extraction process and describe key considerations for its successful implementation. BCoV is a single-stranded positive-sense RNA virus with a genome size of approximately 31 kbp. It was first identified as the causative agent of severe diarrhea in neonatal calves [12]. Like SARS-CoV-2, BCoV belongs to the coronaviridae family of enveloped RNA viruses, and has a similarly-sized genome. Given the morphological similarities to SARS-CoV-2 [13,14], many WBS studies have identified BCoV as an ideal candidate for evaluating the efficiency of wastewater extraction methods [4,15,16]. In addition, BCoV is routinely labelled as an “exogenous” control not present in municipal wastewater [17], allowing for controlled and measurable spike-ins. As such, BCoV is one of the most widely used process controls in WBS [16,18], which is why it was selected for this method. Pepper mild mottle virus (PMMoV) is highly abundant in wastewater samples [19] and is commonly used in WBS as a human fecal indicator as well as to indirectly measure PCR inhibition [20,21]. Similar to BCoV, PMMoV is a single-stranded positive-sense RNA virus, but with a smaller genome of approximately 6.3 kbp and is non-enveloped [22,23]. Together, BCoV and PMMoV are important components of a WBS’ QA/QC program, with the former required for efficiency measures and the latter used as a fecal indicator to ensure samples are representative of the site’s population. Both BCoV and PMMoV are regularly measured using PCR, with many laboratories incorporating the use of multiplex reactions to maximize resources. The use of BCoV and PMMoV in a multiplex RT-qPCR reaction is beneficial given that both can be highly abundant at similar magnitudes and therefore less likely to interfere with the other’s signal. Previous WBS work has shown the use of process controls in multiplex reactions [[24], [25], [26]], however, the majority employs the use of dPCR [18,27]. Although dPCR is reported to increase sensitivity [28,29] and minimize the effects of inhibition [30], its use can be accompanied by higher operating costs, limited reagent flexibility, and lower throughput compared to qPCR. Therefore, the BCoV and PMMoV duplex RT-qPCR method outlined here can provide a viable alternative along with validation information. Method details Safety considerations and precautions. 1.We suggest that biosafety level 2 (BSL-2) controls be used when handling wastewater samples as they may contain potentially hazardous pathogens and chemicals. Personal protective equipment (PPE) should be used to meet BSL-2 requirements, including working in a biosafety cabinet (BSC), wearing gloves, lab coat, gown, and eye/face splash protection. We suggest that biosafety level 2 (BSL-2) controls be used when handling wastewater samples as they may contain potentially hazardous pathogens and chemicals. Personal protective equipment (PPE) should be used to meet BSL-2 requirements, including working in a biosafety cabinet (BSC), wearing gloves, lab coat, gown, and eye/face splash protection. 2.To minimize contamination of downstream molecular reagents and nucleic acid samples, template-free reagents and template-containing materials should be kept in separate work areas following a unidirectional workflow. Additionally, work should be completed within a BSC treated to remove RNA, DNA, and RNases. To minimize contamination of downstream molecular reagents and nucleic acid samples, template-free reagents and template-containing materials should be kept in separate work areas following a unidirectional workflow. Additionally, work should be completed within a BSC treated to remove RNA, DNA, and RNases. Collection of primary influent wastewater 1.Collect 500 mL of 24-hour composite primary influent wastewater. This volume provides a more stable and representative view of the site being sampled compared to smaller volumes which may introduce variability. In addition, 500 mL of wastewater is a large enough volume to allow for multiple tests for various targets being monitored, while also small enough to facilitate shipping from wastewater treatment plants (WWTPs) to WBS laboratories. Alternatively, grab samples can be used, however, they may not be entirely representative of variations in wastewater composition over the course of a day. Collect 500 mL of 24-hour composite primary influent wastewater. This volume provides a more stable and representative view of the site being sampled compared to smaller volumes which may introduce variability. In addition, 500 mL of wastewater is a large enough volume to allow for multiple tests for various targets being monitored, while also small enough to facilitate shipping from wastewater treatment plants (WWTPs) to WBS laboratories. Alternatively, grab samples can be used, however, they may not be entirely representative of variations in wastewater composition over the course of a day. 2.Store collected wastewater at 4 °C for transport and temporary storage until extraction. Store collected wastewater at 4 °C for transport and temporary storage until extraction. Preparation and quantification of BCoV spike-in material 1.Reconstitution of BCoV vaccine.a.Mix the BOVILIS® CORONAVIRUS Diluent by inverting the vial 10 times.b.Transfer all 2.0 mL of the BOVILIS® CORONAVIRUS Diluent to the BOVILIS® CORONAVIRUS vaccine vial with a syringe and resuspend by inverting 10 times.c.Transfer all of the resuspended vaccine into an intermediate vessel (e.g. 5.0 mL screw-cap tube) and split into single-use aliquots.d.Store aliquots at −80 °C. Reconstitution of BCoV vaccine.a.Mix the BOVILIS® CORONAVIRUS Diluent by inverting the vial 10 times.b.Transfer all 2.0 mL of the BOVILIS® CORONAVIRUS Diluent to the BOVILIS® CORONAVIRUS vaccine vial with a syringe and resuspend by inverting 10 times.c.Transfer all of the resuspended vaccine into an intermediate vessel (e.g. 5.0 mL screw-cap tube) and split into single-use aliquots.d.Store aliquots at −80 °C. a.Mix the BOVILIS® CORONAVIRUS Diluent by inverting the vial 10 times. Mix the BOVILIS® CORONAVIRUS Diluent by inverting the vial 10 times. b.Transfer all 2.0 mL of the BOVILIS® CORONAVIRUS Diluent to the BOVILIS® CORONAVIRUS vaccine vial with a syringe and resuspend by inverting 10 times. Transfer all 2.0 mL of the BOVILIS® CORONAVIRUS Diluent to the BOVILIS® CORONAVIRUS vaccine vial with a syringe and resuspend by inverting 10 times. c.Transfer all of the resuspended vaccine into an intermediate vessel (e.g. 5.0 mL screw-cap tube) and split into single-use aliquots. Transfer all of the resuspended vaccine into an intermediate vessel (e.g. 5.0 mL screw-cap tube) and split into single-use aliquots. d.Store aliquots at −80 °C. Store aliquots at −80 °C. 2.Absolute quantification of resuspended BCoV Vaccine.a.Heat Lysis.i.Thaw an aliquot of reconstituted BCoV vaccine and transfer 20 µL to a 0.2 mL PCR tube.ii.Perform heat lysis by incubating on a thermal cycler for 10 min at 95 °C followed by 5 min at 4 °C [31].iii.Proceed immediately to quantification (do not store).b.Absolute Q™ Digital PCR quantification.i.Prepare a 20X BCoV primer-probe mixture using only BCoV primers/probes (Table 1; Table 2).ii.Prepare four RT-dPCR pre-reactions with the 20X mixture prepared above (Table 3).iii.Load 9 µL of each prepared pre-reaction into the MAP16 plate.iv.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate.v.Reaction thermal cycling parameters (Table 4).c.Quantification calculation.i.Calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of the prepared BCoV vaccine. Absolute quantification of resuspended BCoV Vaccine.a.Heat Lysis.i.Thaw an aliquot of reconstituted BCoV vaccine and transfer 20 µL to a 0.2 mL PCR tube.ii.Perform heat lysis by incubating on a thermal cycler for 10 min at 95 °C followed by 5 min at 4 °C [31].iii.Proceed immediately to quantification (do not store).b.Absolute Q™ Digital PCR quantification.i.Prepare a 20X BCoV primer-probe mixture using only BCoV primers/probes (Table 1; Table 2).ii.Prepare four RT-dPCR pre-reactions with the 20X mixture prepared above (Table 3).iii.Load 9 µL of each prepared pre-reaction into the MAP16 plate.iv.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate.v.Reaction thermal cycling parameters (Table 4).c.Quantification calculation.i.Calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of the prepared BCoV vaccine. a.Heat Lysis.i.Thaw an aliquot of reconstituted BCoV vaccine and transfer 20 µL to a 0.2 mL PCR tube.ii.Perform heat lysis by incubating on a thermal cycler for 10 min at 95 °C followed by 5 min at 4 °C [31].iii.Proceed immediately to quantification (do not store). Heat Lysis.i.Thaw an aliquot of reconstituted BCoV vaccine and transfer 20 µL to a 0.2 mL PCR tube.ii.Perform heat lysis by incubating on a thermal cycler for 10 min at 95 °C followed by 5 min at 4 °C [31].iii.Proceed immediately to quantification (do not store). i.Thaw an aliquot of reconstituted BCoV vaccine and transfer 20 µL to a 0.2 mL PCR tube. Thaw an aliquot of reconstituted BCoV vaccine and transfer 20 µL to a 0.2 mL PCR tube. ii.Perform heat lysis by incubating on a thermal cycler for 10 min at 95 °C followed by 5 min at 4 °C [31]. Perform heat lysis by incubating on a thermal cycler for 10 min at 95 °C followed by 5 min at 4 °C [31]. iii.Proceed immediately to quantification (do not store). Proceed immediately to quantification (do not store). b.Absolute Q™ Digital PCR quantification.i.Prepare a 20X BCoV primer-probe mixture using only BCoV primers/probes (Table 1; Table 2).ii.Prepare four RT-dPCR pre-reactions with the 20X mixture prepared above (Table 3).iii.Load 9 µL of each prepared pre-reaction into the MAP16 plate.iv.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate.v.Reaction thermal cycling parameters (Table 4). Absolute Q™ Digital PCR quantification.i.Prepare a 20X BCoV primer-probe mixture using only BCoV primers/probes (Table 1; Table 2).ii.Prepare four RT-dPCR pre-reactions with the 20X mixture prepared above (Table 3).iii.Load 9 µL of each prepared pre-reaction into the MAP16 plate.iv.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate.v.Reaction thermal cycling parameters (Table 4). i.Prepare a 20X BCoV primer-probe mixture using only BCoV primers/probes (Table 1; Table 2). Prepare a 20X BCoV primer-probe mixture using only BCoV primers/probes (Table 1; Table 2). ii.Prepare four RT-dPCR pre-reactions with the 20X mixture prepared above (Table 3). Prepare four RT-dPCR pre-reactions with the 20X mixture prepared above (Table 3). iii.Load 9 µL of each prepared pre-reaction into the MAP16 plate. Load 9 µL of each prepared pre-reaction into the MAP16 plate. iv.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate. Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate. v.Reaction thermal cycling parameters (Table 4). Reaction thermal cycling parameters (Table 4). c.Quantification calculation.i.Calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of the prepared BCoV vaccine. Quantification calculation.i.Calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of the prepared BCoV vaccine. i.Calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of the prepared BCoV vaccine. Calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of the prepared BCoV vaccine. Table 1Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) multiplex dPCR and RT-qPCR assay sequences.Table 1 dummy alt textAssayReagentSequenceSourcePMMoVForward PrimerGAGTGGTTTGACCTTAACGTTTGA[32] & this manuscript*Reverse PrimerTTGTCGGTTGCAATGCAAGTProbeFAM-CCTACCGAAGCAAATG-MGBNFQBCoVForward PrimerCTGGAAGTTGGTGGAGTT[33]Reverse PrimerATTATCGGCCTAACATACATCProbeHEX-CCTTCATATCTATACACATCAAGTTGTT-BHQ1* PMMoV forward primer has been modified in-house from the original publication to more closely align with current circulating strains. Please note that PMMoV is endogenously present in wastewater and therefore is not spiked-in to wastewater samples. Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) multiplex dPCR and RT-qPCR assay sequences. * PMMoV forward primer has been modified in-house from the original publication to more closely align with current circulating strains. Please note that PMMoV is endogenously present in wastewater and therefore is not spiked-in to wastewater samples. Table 2dPCR quantification primer-probe mix (20X) formula.Table 2 dummy alt textReagent[Stock](µM)1X [Reaction] (µM)20X [Reaction] (µM)StockVolume(µL)Forward Primer1000.9018.09.0Reverse Primer1000.9018.09.0Probe1000.255.02.51X TE Buffer———29.5Total Volume50.0Final reaction concentrations of 0.90 µM (primer) and 0.25 µM (probe) are used for dPCR quantification. dPCR quantification primer-probe mix (20X) formula. Final reaction concentrations of 0.90 µM (primer) and 0.25 µM (probe) are used for dPCR quantification. Table 3Applied Biosystems QuantStudio Absolute Q™ digital PCR system pre-reaction mixture formula.Table 3 dummy alt textReagent[Stock][Final]1 ReactionVolume(µL)4 ReactionsVolume(µL)Absolute Q™ 1-step RT-dPCR Master Mix4X1X3.012.0Primer-Probe Mixture20X1X0.62.41X TE Buffer——6.425.6Template (Diluted 1:2500 in 1XTE)——2.08.0Pre-reaction Total——12.048.0A 12 µL pre-reaction is made with these components. Next, 9 µL of this pre-reaction mixture is loaded into each well of the MAP16 reaction plate. Four reactions using one MAP16 plate column are used for quantification of BCoV vaccine. Applied Biosystems QuantStudio Absolute Q™ digital PCR system pre-reaction mixture formula. A 12 µL pre-reaction is made with these components. Next, 9 µL of this pre-reaction mixture is loaded into each well of the MAP16 reaction plate. Four reactions using one MAP16 plate column are used for quantification of BCoV vaccine. Table 4Applied Biosystems QuantStudio Absolute Q™ digital PCR system thermal cycling for bovine coronavirus.Table 4 dummy alt textStepTemperature(°C)Time(mm:ss)CyclesReverse Transcription5510:00Pre-Heat9610:00Denaturation9600:0540Annealing/Extension6000:15 Applied Biosystems QuantStudio Absolute Q™ digital PCR system thermal cycling for bovine coronavirus. Equation 1. Applied Biosystems QuantStudio Absolute Q™ Digital PCR System quantification back-calculation quantification. C = concentration in genome copies per µL (cp/µL): Cstock = back-calculated stock concentration, CABQ = raw dPCR instrument diluted template concentration determination. V = volume (µL): VpreRXN = volume of the pre-reaction (12 µL), Vtemplate = volume of diluted template added to pre-reaction (2 µL). DF = dilution factor. Preparation and quantification of synthetic positive control material 1.Reconstitution of lyophilized synthetic positive control material.a.Resuspend lyophilized synthetic DNA positive control material (BCoV and PMMoV; Table 5) to an estimated 5 × 109 copies/µL in 1X TE buffer as specified by commercial vendor [34], and divide into single-use aliquots stored at −80 °C. Reconstitution of lyophilized synthetic positive control material.a.Resuspend lyophilized synthetic DNA positive control material (BCoV and PMMoV; Table 5) to an estimated 5 × 109 copies/µL in 1X TE buffer as specified by commercial vendor [34], and divide into single-use aliquots stored at −80 °C. a.Resuspend lyophilized synthetic DNA positive control material (BCoV and PMMoV; Table 5) to an estimated 5 × 109 copies/µL in 1X TE buffer as specified by commercial vendor [34], and divide into single-use aliquots stored at −80 °C. Resuspend lyophilized synthetic DNA positive control material (BCoV and PMMoV; Table 5) to an estimated 5 × 109 copies/µL in 1X TE buffer as specified by commercial vendor [34], and divide into single-use aliquots stored at −80 °C. 2.Quantification of reconstituted synthetic positive control material.a.Prepare separate 20X primer-probe mixtures for BCoV and PMMoV (Table 1; Table 2).b.Prepare four dPCR pre-reactions for BCoV and four for PMMoV (Table 6).c.Load 9 µL of each prepared pre-reaction into the MAP16 plate.d.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate.e.Thermal cycle (Table 7).f.Back-calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of each positive control oligo. Quantification of reconstituted synthetic positive control material.a.Prepare separate 20X primer-probe mixtures for BCoV and PMMoV (Table 1; Table 2).b.Prepare four dPCR pre-reactions for BCoV and four for PMMoV (Table 6).c.Load 9 µL of each prepared pre-reaction into the MAP16 plate.d.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate.e.Thermal cycle (Table 7).f.Back-calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of each positive control oligo. a.Prepare separate 20X primer-probe mixtures for BCoV and PMMoV (Table 1; Table 2). Prepare separate 20X primer-probe mixtures for BCoV and PMMoV (Table 1; Table 2). b.Prepare four dPCR pre-reactions for BCoV and four for PMMoV (Table 6). Prepare four dPCR pre-reactions for BCoV and four for PMMoV (Table 6). c.Load 9 µL of each prepared pre-reaction into the MAP16 plate. Load 9 µL of each prepared pre-reaction into the MAP16 plate. d.Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate. Load 15 µL of Absolute Q™ isolation buffer to the MAP16 plate. e.Thermal cycle (Table 7). Thermal cycle (Table 7). f.Back-calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of each positive control oligo. Back-calculate the stock concentration of each measurement (Equation 1) and average all results to obtain the stock concentration of each positive control oligo. Table 5Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) duplex positive control sequences.Table 5 dummy alt textPositive ControlLength(bp)Molecular Weight(g/mol)SequenceBCoV Positive Control Sequence250154,319.91GGCCATTATTATGTGGATTGTGTATTTTGTGAATAGTATCAGGTTGTTTATTAGAACTGGAAGTTGGTGGAGTTTCAACCCAGAAACAAACAACTTGATGTGTATAGATATGAAGGGAAGGATGTATGTTAGGCCGATAATTGAGGACTACCATACCCTTACGGTCACAATAATACGTGGTCATCTTTACATGCAAGGTATAAAACTAGGTACTGGCTATTCTTTGTCAGATTTGCCAGCTTATGTGACTPMMoV Positive Control Sequence15796,864.18ATTTGACTTTGTTGTATGTCAAATATAGAGCTTATGAATTAGGTTTCAAATGAGAGTGGTTTGACCTTAACGTTTGAGAGGCCTACCGAAGCAAATGTCGCACTTGCATTGCAACCGACAATTACATCAAAGGAAGACCTTTTTCAACATATGTAAT Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) duplex positive control sequences. Table 6Applied Biosystems QuantStudio Absolute Q™ digital PCR system pre-reaction mixture (12 µL) formula for DNA quantification of synthetic DNA oligos.Table 6 dummy alt textReagent[Stock][Final]1 ReactionVolume(µL)4 ReactionsVolume(µL)Absolute Q™ DNA Digital PCR Master Mix5X1X2.49.6Primer-Probe Mixture20X1X0.62.41X TE Buffer——7.028.0Template (Diluted 1:500,000 in 1X TE, ∼1 × 104 cp/µL)——2.08.0Pre-reaction Total——12.048.0A portion of this pre-reaction mixture (9 µL) is loaded into the MAP16 reaction plate. Applied Biosystems QuantStudio Absolute Q™ digital PCR system pre-reaction mixture (12 µL) formula for DNA quantification of synthetic DNA oligos. A portion of this pre-reaction mixture (9 µL) is loaded into the MAP16 reaction plate. Table 7Applied Biosystems QuantStudio Absolute Q™ digital PCR system thermal cycling for synthetic bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) DNA control oligos.Table 7 dummy alt textStepTemperature(°C)Time(mm:ss)CyclesPre-Heat9610:00Denaturation9600:0540Annealing/Extension6000:15 Applied Biosystems QuantStudio Absolute Q™ digital PCR system thermal cycling for synthetic bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) DNA control oligos. Nucleic acid extraction from solids-fraction of wastewater 1.BCoV spike and incubation.a.Shake the 500 mL wastewater influent sample bottle for four seconds or until fully mixed.b.Aliquot 30 mL of mixed wastewater into a 50 mL conical tube.c.Pipette 5 µL (∼1.5 × 107 copies) of the quantified BCoV vaccine into the 30 mL wastewater aliquot,d.Vortex the wastewater aliquot for ten seconds.e.Incubate the wastewater aliquot at 4 °C overnight (minimum 18 h, maximum 64 h). BCoV spike and incubation.a.Shake the 500 mL wastewater influent sample bottle for four seconds or until fully mixed.b.Aliquot 30 mL of mixed wastewater into a 50 mL conical tube.c.Pipette 5 µL (∼1.5 × 107 copies) of the quantified BCoV vaccine into the 30 mL wastewater aliquot,d.Vortex the wastewater aliquot for ten seconds.e.Incubate the wastewater aliquot at 4 °C overnight (minimum 18 h, maximum 64 h). a.Shake the 500 mL wastewater influent sample bottle for four seconds or until fully mixed. Shake the 500 mL wastewater influent sample bottle for four seconds or until fully mixed. b.Aliquot 30 mL of mixed wastewater into a 50 mL conical tube. Aliquot 30 mL of mixed wastewater into a 50 mL conical tube. c.Pipette 5 µL (∼1.5 × 107 copies) of the quantified BCoV vaccine into the 30 mL wastewater aliquot, Pipette 5 µL (∼1.5 × 107 copies) of the quantified BCoV vaccine into the 30 mL wastewater aliquot, d.Vortex the wastewater aliquot for ten seconds. Vortex the wastewater aliquot for ten seconds. e.Incubate the wastewater aliquot at 4 °C overnight (minimum 18 h, maximum 64 h). Incubate the wastewater aliquot at 4 °C overnight (minimum 18 h, maximum 64 h). 2.Wastewater solids pellet lysis.a.Following incubation, pellet the wastewater aliquot by centrifugation at 4200 x g for 22 min at 4 °C.b.Discard the clarified supernatant, retaining the wastewater solids pellet.c.Resuspend the pellet in 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol).d.Transfer the resuspended pellet to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads.e.Transfer 200 µL 1X TE buffer and 5 µL of quantified BCoV vaccine to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads and 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to act as the Blank Extraction Control.f.Load the 2.0 mL bead-beating tubes into a bead mill homogenizer and run the bead-beating program (4 cycles of 30 s at 6 m/s with 10 s of dwell time).g.Clarify the bead-beating tubes by centrifugation at 14,000 x g for 3 min at 4 °C. Wastewater solids pellet lysis.a.Following incubation, pellet the wastewater aliquot by centrifugation at 4200 x g for 22 min at 4 °C.b.Discard the clarified supernatant, retaining the wastewater solids pellet.c.Resuspend the pellet in 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol).d.Transfer the resuspended pellet to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads.e.Transfer 200 µL 1X TE buffer and 5 µL of quantified BCoV vaccine to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads and 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to act as the Blank Extraction Control.f.Load the 2.0 mL bead-beating tubes into a bead mill homogenizer and run the bead-beating program (4 cycles of 30 s at 6 m/s with 10 s of dwell time).g.Clarify the bead-beating tubes by centrifugation at 14,000 x g for 3 min at 4 °C. a.Following incubation, pellet the wastewater aliquot by centrifugation at 4200 x g for 22 min at 4 °C. Following incubation, pellet the wastewater aliquot by centrifugation at 4200 x g for 22 min at 4 °C. b.Discard the clarified supernatant, retaining the wastewater solids pellet. Discard the clarified supernatant, retaining the wastewater solids pellet. c.Resuspend the pellet in 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol). Resuspend the pellet in 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol). d.Transfer the resuspended pellet to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads. Transfer the resuspended pellet to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads. e.Transfer 200 µL 1X TE buffer and 5 µL of quantified BCoV vaccine to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads and 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to act as the Blank Extraction Control. Transfer 200 µL 1X TE buffer and 5 µL of quantified BCoV vaccine to a 2.0 mL screw-cap microcentrifuge bead-beating tube containing 200 µL of 0.5 mm zirconia/silica beads and 700 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to act as the Blank Extraction Control. f.Load the 2.0 mL bead-beating tubes into a bead mill homogenizer and run the bead-beating program (4 cycles of 30 s at 6 m/s with 10 s of dwell time). Load the 2.0 mL bead-beating tubes into a bead mill homogenizer and run the bead-beating program (4 cycles of 30 s at 6 m/s with 10 s of dwell time). g.Clarify the bead-beating tubes by centrifugation at 14,000 x g for 3 min at 4 °C. Clarify the bead-beating tubes by centrifugation at 14,000 x g for 3 min at 4 °C. 3.Nucleic acid purification.a.Add 2 µL of 1 mg/mL carrier RNA to a 96-deep well MP96 processing cartridge.b.Transfer up to 950 µL of lysed sample from the bead beating tube to the processing cartridge as described in Fig. 1. The MP96 processing cartridge holds a maximum of 1 mL. The addition of a maximum volume of 950 µL will help prevent overflows.c.Transfer 5 µL of quantified BCoV vaccine and 900 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to another well to act as the Buffer RLT Control. The 900 µL is a reflection of the average amount of lysate typically obtained from processing 30 mL of wastewater.d.Briefly centrifuge the processing cartridge to collect all liquid from the sides of the wells.e.Load the MagNA Pure 96 System with the processing cartridge and kit reagent trays, then run the processing protocol: 'Viral NA Plasma ext lys LV' protocol with the elution volume option set to 100 µL.f.Store eluted nucleic acids at 4 °C for immediate use, or at −80 °C for long-term storage. Nucleic acid purification.a.Add 2 µL of 1 mg/mL carrier RNA to a 96-deep well MP96 processing cartridge.b.Transfer up to 950 µL of lysed sample from the bead beating tube to the processing cartridge as described in Fig. 1. The MP96 processing cartridge holds a maximum of 1 mL. The addition of a maximum volume of 950 µL will help prevent overflows.c.Transfer 5 µL of quantified BCoV vaccine and 900 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to another well to act as the Buffer RLT Control. The 900 µL is a reflection of the average amount of lysate typically obtained from processing 30 mL of wastewater.d.Briefly centrifuge the processing cartridge to collect all liquid from the sides of the wells.e.Load the MagNA Pure 96 System with the processing cartridge and kit reagent trays, then run the processing protocol: 'Viral NA Plasma ext lys LV' protocol with the elution volume option set to 100 µL.f.Store eluted nucleic acids at 4 °C for immediate use, or at −80 °C for long-term storage. a.Add 2 µL of 1 mg/mL carrier RNA to a 96-deep well MP96 processing cartridge. Add 2 µL of 1 mg/mL carrier RNA to a 96-deep well MP96 processing cartridge. b.Transfer up to 950 µL of lysed sample from the bead beating tube to the processing cartridge as described in Fig. 1. The MP96 processing cartridge holds a maximum of 1 mL. The addition of a maximum volume of 950 µL will help prevent overflows. Transfer up to 950 µL of lysed sample from the bead beating tube to the processing cartridge as described in Fig. 1. The MP96 processing cartridge holds a maximum of 1 mL. The addition of a maximum volume of 950 µL will help prevent overflows. c.Transfer 5 µL of quantified BCoV vaccine and 900 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to another well to act as the Buffer RLT Control. The 900 µL is a reflection of the average amount of lysate typically obtained from processing 30 mL of wastewater. Transfer 5 µL of quantified BCoV vaccine and 900 µL of buffer RLT (supplemented with 1% v/v 2-mercaptoethanol) to another well to act as the Buffer RLT Control. The 900 µL is a reflection of the average amount of lysate typically obtained from processing 30 mL of wastewater. d.Briefly centrifuge the processing cartridge to collect all liquid from the sides of the wells. Briefly centrifuge the processing cartridge to collect all liquid from the sides of the wells. e.Load the MagNA Pure 96 System with the processing cartridge and kit reagent trays, then run the processing protocol: 'Viral NA Plasma ext lys LV' protocol with the elution volume option set to 100 µL. Load the MagNA Pure 96 System with the processing cartridge and kit reagent trays, then run the processing protocol: 'Viral NA Plasma ext lys LV' protocol with the elution volume option set to 100 µL. f.Store eluted nucleic acids at 4 °C for immediate use, or at −80 °C for long-term storage. Store eluted nucleic acids at 4 °C for immediate use, or at −80 °C for long-term storage. Transferring the clarified lysate from the bead beating tube without disturbing the pellet. Push the pipette tip to the side wall opposite of the angled pellet to reduce the solids material aspirating into the pipette tip. Created in BioRender. Mejia, E. (2026)https://BioRender.com/iq5chbg. BCoV and PMMoV RT-qPCR BCoV and PMMoV multiplex 1.Prepare BCoV-PMMoV duplex reactions in a 96-well low-bind PCR plate (Table 8, Table 9).a.Sample testing: duplicate reactions for both neat and diluted extracts (1:10 in 1X TE), for a total of four reactions per sample.b.Negative controls: One reaction for each: no-template control (NTC), blank extraction control, and buffer RLT control (three total reactions per plate).c.Positive controls: one of the following (standard curve or high and low control reactions).i.Standard curve.1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate).2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate).ii.High and low control reactions (the standard curve is ran separately and applied to all downstream quantification with the same mastermix batch; four total reactions per plate).1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C.2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material.3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. Prepare BCoV-PMMoV duplex reactions in a 96-well low-bind PCR plate (Table 8, Table 9).a.Sample testing: duplicate reactions for both neat and diluted extracts (1:10 in 1X TE), for a total of four reactions per sample.b.Negative controls: One reaction for each: no-template control (NTC), blank extraction control, and buffer RLT control (three total reactions per plate).c.Positive controls: one of the following (standard curve or high and low control reactions).i.Standard curve.1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate).2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate).ii.High and low control reactions (the standard curve is ran separately and applied to all downstream quantification with the same mastermix batch; four total reactions per plate).1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C.2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material.3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. a.Sample testing: duplicate reactions for both neat and diluted extracts (1:10 in 1X TE), for a total of four reactions per sample. Sample testing: duplicate reactions for both neat and diluted extracts (1:10 in 1X TE), for a total of four reactions per sample. b.Negative controls: One reaction for each: no-template control (NTC), blank extraction control, and buffer RLT control (three total reactions per plate). Negative controls: One reaction for each: no-template control (NTC), blank extraction control, and buffer RLT control (three total reactions per plate). c.Positive controls: one of the following (standard curve or high and low control reactions).i.Standard curve.1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate).2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate).ii.High and low control reactions (the standard curve is ran separately and applied to all downstream quantification with the same mastermix batch; four total reactions per plate).1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C.2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material.3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. Positive controls: one of the following (standard curve or high and low control reactions).i.Standard curve.1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate).2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate).ii.High and low control reactions (the standard curve is ran separately and applied to all downstream quantification with the same mastermix batch; four total reactions per plate).1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C.2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material.3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. i.Standard curve.1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate).2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate). Standard curve.1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate).2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate). 1.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate). Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified PMMoV synthetic positive control material (15 total reactions per plate). 2.Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate). Triplicate reactions of a five-point, tenfold serial dilution starting from 1 × 106 cp/µL to 1 × 102 cp/µL of quantified BCoV synthetic positive control material (15 total reactions per plate). ii.High and low control reactions (the standard curve is ran separately and applied to all downstream quantification with the same mastermix batch; four total reactions per plate).1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C.2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material.3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. High and low control reactions (the standard curve is ran separately and applied to all downstream quantification with the same mastermix batch; four total reactions per plate).1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C.2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material.3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. 1.Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C. Mastermix may be made in advance (containing enzymes, primers, probes, and buffer) and stored at −30 °C. 2.Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material. Duplicate reactions of the ‘High Control’ containing both 1 × 105 cp/µL of quantified PMMoV synthetic positive control material and 1 × 105 cp/µL of quantified BCoV synthetic positive control material. 3.Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. Duplicate reactions of the ‘Low Control’ containing both 1 × 103 cp/µL of quantified PMMoV synthetic positive control material and 1 × 103 cp/µL of quantified BCoV synthetic positive control material. 2.Thermal cycle the BCoV and PMMoV multiplex reactions (Table 10). Thermal cycle the BCoV and PMMoV multiplex reactions (Table 10). Table 8Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) multiplex RT-qPCR testing matrix.Table 8 dummy alt textSampleSample DescriptionConcentration(cp/µL)Technical Replicates(n)Wastewater sampleNeat nucleic acids sample–2Sample nucleic acids diluted 1:10 in 1X TE–2Negative controlsNo-template control (NTC)–1Blank extraction control–1Buffer RLT extraction control–1Positive controlsPMMoV standard curve*1 × 10631 × 10531 × 10431 × 10331 × 1023BCoV standard curve*1 × 10631 × 10531 × 10431 × 10331 × 1023PMMoV & BCoV high control†1 × 105 ‡2PMMoV & BCoV low control†1 × 103 ‡2* Use the indicated positive controls when including the standard curve on the reaction plate with samples.† Use the indicated positive controls when preparing a large volume of mastermix and running the standard curve separately in advance.‡ High and low control aliquots should contain 1 × 105 or 1 × 103 of both PMMoV and BCoV (totalling 2 × 105 or 2 × 103 combined copies, respectively). Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) multiplex RT-qPCR testing matrix. * Use the indicated positive controls when including the standard curve on the reaction plate with samples. † Use the indicated positive controls when preparing a large volume of mastermix and running the standard curve separately in advance. ‡ High and low control aliquots should contain 1 × 105 or 1 × 103 of both PMMoV and BCoV (totalling 2 × 105 or 2 × 103 combined copies, respectively). Table 9Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) RT-qPCR multiplex reaction.Table 9 dummy alt textReagent[Stock][Final]1 ReactionVolume(µL)1000 ReactionsVolume(µL)TaqPath™ 1-Step RT-qPCR Master Mix, CG4X1X5.05000PMMoV Forward Primer100 µM0.6 µM0.12120PMMoV Reverse Primer100 µM0.6 µM0.12120PMMoV Probe (FAM)100 µM0.2 µM0.0440BCoV Forward Primer100 µM0.6 µM0.12120BCoV Reverse Primer100 µM0.6 µM0.12120BCoV Probe (HEX)100 µM0.4 µM0.08801X TE––9.409400Template––5.0–Reaction Total––20.0–Sequences for forward primers, reverse primers, and probes for the BCoV-PMMoV multiplex can be found in Table 1. Bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) RT-qPCR multiplex reaction. Sequences for forward primers, reverse primers, and probes for the BCoV-PMMoV multiplex can be found in Table 1. Table 10Applied Biosystems QuantStudio PCR System thermal cycling for bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) multiplex RT-qPCR.Table 10 dummy alt textStepTemperature(°C)Time(mm:ss)CyclesUNG2502:00Reverse Transcription5015:00Pre-Heat9610:00Denaturation9600:0540Annealing/Extension6000:30Post-Read Optics6000:30 Applied Biosystems QuantStudio PCR System thermal cycling for bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) multiplex RT-qPCR. Quality assurance and data analysis 1.Standard curve.a.Calculate a linear standard curve of logarithmic (base 10) genome copies per reaction vs average Ct for each standard curve dilution point (slope and y-intercept).b.Standard curve efficiency must be between 90–110% and the R-squared must be greater than 0.9800 [35].c.The intercepts for PMMoV and BCoV conform to the standard deviation of the previous mastermix standard curves based on Westgard Rules for longitudinal stability [36]. Standard curve.a.Calculate a linear standard curve of logarithmic (base 10) genome copies per reaction vs average Ct for each standard curve dilution point (slope and y-intercept).b.Standard curve efficiency must be between 90–110% and the R-squared must be greater than 0.9800 [35].c.The intercepts for PMMoV and BCoV conform to the standard deviation of the previous mastermix standard curves based on Westgard Rules for longitudinal stability [36]. a.Calculate a linear standard curve of logarithmic (base 10) genome copies per reaction vs average Ct for each standard curve dilution point (slope and y-intercept). Calculate a linear standard curve of logarithmic (base 10) genome copies per reaction vs average Ct for each standard curve dilution point (slope and y-intercept). b.Standard curve efficiency must be between 90–110% and the R-squared must be greater than 0.9800 [35]. Standard curve efficiency must be between 90–110% and the R-squared must be greater than 0.9800 [35]. c.The intercepts for PMMoV and BCoV conform to the standard deviation of the previous mastermix standard curves based on Westgard Rules for longitudinal stability [36]. The intercepts for PMMoV and BCoV conform to the standard deviation of the previous mastermix standard curves based on Westgard Rules for longitudinal stability [36]. 2.High and low positive controls (if applicable).a.High and low Cts conform to the standard deviation of the previous control reactions based on Westgard Rules for longitudinal stability [36]. High and low positive controls (if applicable).a.High and low Cts conform to the standard deviation of the previous control reactions based on Westgard Rules for longitudinal stability [36]. a.High and low Cts conform to the standard deviation of the previous control reactions based on Westgard Rules for longitudinal stability [36]. High and low Cts conform to the standard deviation of the previous control reactions based on Westgard Rules for longitudinal stability [36]. 3.Negative controls.a.All negative controls must have no signal detected for the PMMoV and BCoV assay. Negative controls.a.All negative controls must have no signal detected for the PMMoV and BCoV assay. a.All negative controls must have no signal detected for the PMMoV and BCoV assay. All negative controls must have no signal detected for the PMMoV and BCoV assay. 4.Wastewater samples.a.Inhibition.i.Calculate the PMMoV Ct difference between diluted and undiluted wastewater samples.ii.Inhibition is classified as ΔCt < 1.6 (determined empirically through longitudinal monitoring of PMMoV in wastewater samples and calculating the ∆Ct that would result in 5% of samples labelled as inhibited). Please note that this can vary between laboratories.b.PMMoV viral load quantification (Equation 2).c.BCoV viral load quantification (Equation 3).d.BCoV extraction efficiency (Equation 4). Wastewater samples.a.Inhibition.i.Calculate the PMMoV Ct difference between diluted and undiluted wastewater samples.ii.Inhibition is classified as ΔCt < 1.6 (determined empirically through longitudinal monitoring of PMMoV in wastewater samples and calculating the ∆Ct that would result in 5% of samples labelled as inhibited). Please note that this can vary between laboratories.b.PMMoV viral load quantification (Equation 2).c.BCoV viral load quantification (Equation 3).d.BCoV extraction efficiency (Equation 4). a.Inhibition.i.Calculate the PMMoV Ct difference between diluted and undiluted wastewater samples.ii.Inhibition is classified as ΔCt < 1.6 (determined empirically through longitudinal monitoring of PMMoV in wastewater samples and calculating the ∆Ct that would result in 5% of samples labelled as inhibited). Please note that this can vary between laboratories. Inhibition.i.Calculate the PMMoV Ct difference between diluted and undiluted wastewater samples.ii.Inhibition is classified as ΔCt < 1.6 (determined empirically through longitudinal monitoring of PMMoV in wastewater samples and calculating the ∆Ct that would result in 5% of samples labelled as inhibited). Please note that this can vary between laboratories. i.Calculate the PMMoV Ct difference between diluted and undiluted wastewater samples. Calculate the PMMoV Ct difference between diluted and undiluted wastewater samples. ii.Inhibition is classified as ΔCt < 1.6 (determined empirically through longitudinal monitoring of PMMoV in wastewater samples and calculating the ∆Ct that would result in 5% of samples labelled as inhibited). Please note that this can vary between laboratories. Inhibition is classified as ΔCt < 1.6 (determined empirically through longitudinal monitoring of PMMoV in wastewater samples and calculating the ∆Ct that would result in 5% of samples labelled as inhibited). Please note that this can vary between laboratories. b.PMMoV viral load quantification (Equation 2). PMMoV viral load quantification (Equation 2). c.BCoV viral load quantification (Equation 3). BCoV viral load quantification (Equation 3). d.BCoV extraction efficiency (Equation 4). BCoV extraction efficiency (Equation 4). Equation 2. Wastewater quantification of pepper mild mottle virus (PMMoV). Cwastewater = concentration of PMMoV in wastewater in genome copies per mL (cp/mL). b = standard curve y-intercept. m = standard curve slope. Vtemplate = volume of wastewater template added to the RT-qPCR reaction (5 µL). Velution = RNA extraction elution volume (100 µL). Vwastewater = volume of wastewater processed (30 mL). Equation 3. Wastewater quantification of bovine coronavirus (BCoV). Cwastewater = concentration of BCoV in wastewater in genome copies per extraction (cp/extraction). b = standard curve y-intercept. m = standard curve slope. Vtemplate = volume of wastewater template added to the RT-qPCR reaction (5 µL). Velution = RNA extraction elution volume (100 µL). Equation 4. Extraction efficiency. E = bovine coronavirus (BCoV) extraction efficiency in percent (%). N = number of genome copies per extraction: Nrecovered = number of recovered BCoV copies per extraction, Nseeded = number of BCoV copies spiked into the extraction (determined by prior quantification). Cwastewater = concentration of BCoV recovered in wastewater and is determined in Equation 3. Cstock = previously determined concentration of BCoV vaccine stock. Vstock = volume of vaccine stock spiked into the extraction (5 µL). Method validation Data analysis and visualisation All analyses were performed using R Statistical Software v4.5.1 with rstatix v0.7.2 [37] and dunn.test v1.3.6 [38] packages. The graphical abstract was prepared in Biorender (https://BioRender.com/twc7e3x). Extraction, dilution and quantification of BOVILIS® CORONAVIRUS To ensure an accurate baseline measure of the nucleic acid extracted from the reconstituted BOVILIS® CORONAVIRUS (from here on out referred to as the BCoV vaccine), a comparison of heat lysis [31] and an automated extraction method (using the Roche MP96) was conducted as described in the methods section. For each extraction method, an additional comparison of neat versus a 1:2500 dilution of the BCoV vaccine was performed to assess inhibition. Lastly, incremental volumes of 2 and 20 µL for each dilution condition were also tested for both extraction methods with an additional volume of 200 µL for the MP96 extraction. Our results show that BCoV vaccine extracted via heat lysis and diluted 1:2500 yields a significantly higher concentration compared to all other conditions (p < 0.001, Tukey post-hoc test; Fig. 2). When using a 2 µL volume, the heat-lysed and diluted vaccine yields concentrations that are 62% higher than its neat counterpart (Cdiluted = 4.96×106 cp/µL, Cneat = 3.07×106 cp/µL; p < 0.001, Tukey post-hoc test), and 411% higher than any MP96 extraction (Average CMP96 = 9.71×105 cp/µL; p < 0.001, Tukey post-hoc test). Interestingly, when 20 µL are used, a 324% decrease is observed in the neat heat-lysed BCoV vaccine compared to 2 µL (C20µL, neat = 9.46×105 cp/µL, C2µL, neat = 4.96×106 cp/µL; p < 0.001, Tukey post-hoc test). This drop in concentration is likely due to reagents present in the BCoV vaccine formulation that may act as PCR inhibitors which elicit a stronger effect at higher concentrations [39]. Due to the volume limitations of a PCR reaction, the use of 200 µL of BCoV vaccine was not attempted for the heat lysis extractions. However, no increase in yield was observed when 200 µL of BCoV vaccine was extracted using the MP96. We chose the highest quantifying extraction and quantification method (heat lysis and 1:2500 dilution, 3.01×106 cp/µL) for the baseline quantification of the BCoV vaccine as it should be the closest to the true concentration of the vaccine. Comparison of heat lysis and automated (MP96) nucleic acid extraction from bovine coronavirus (BCoV) vaccine followed by RNA quantification using digital PCR. (A) Effect of dilution on quantification. (B) Effect of extraction method and input volume on quantification. Significant differences are indicated by *p<0.05,**p<0.01,***p<0.001,****p<0,0001 (Tukey post-hoc test with Holm correction). Non-significant differences are omitted. BCoV background in wastewater The use of BCoV as an extraction efficiency control is a widely adopted practice in WBS, yet studies demonstrating its wastewater exogeny are limited. We assessed the in situ levels of BCoV in wastewater samples from seven different Canadian wastewater treatment plants (WWTPs) (Table 11). Additionally, wastewater samples were also pooled to further assess if this resulted in the dilution and cross reaction of the potentially endogenous BCoV signal. Table 11Bovine coronavirus (BCoV) RT-qPCR signals detected from wastewater samples not spiked with BCoV vaccine.Table 11 dummy alt textWWTP IDSite TypeBCoV Ct 1BCoV Ct 2BCoV Ct 3BCoV Average Copies per mLWastewater1AUrbanNDNDNDND1A + 1B + 1C*UrbanNDND–ND2AUrban39.439.539.67.32A + 2B + 2C*Urban38.739.7–9.23A + 3B*Urban40.8†ND–3.1†4AUrbanNDNDNDND5ARemoteNDNDNDND6AUrbanND43.5†ND0.5†7AUrban40.9†NDND2.8†8ARemoteNDNDNDND* Equi-volume pooled wastewater sample composed of multiple WWTPs from the same site.† Ct > 40, amplification beyond thermal cycling standard cycle count.ND - “Not Detected”.WWTP – wastewater treatment plant. Bovine coronavirus (BCoV) RT-qPCR signals detected from wastewater samples not spiked with BCoV vaccine. * Equi-volume pooled wastewater sample composed of multiple WWTPs from the same site. † Ct > 40, amplification beyond thermal cycling standard cycle count. ND - “Not Detected”. WWTP – wastewater treatment plant. Results show that out of a total of ten samples (seven unique WWTPs plus three pooled samples), five were positive for in situ BCoV (Table 11). Of the five positive samples, three came from the unique WWTPs, while two came from the pooled samples. These results show in situ BCoV signals in wastewater samples, regardless of sample pooling. However, Decaro et al. [33] reported that their RT-qPCR assay was also able to detect BCoV-like viruses, including canine respiratory coronavirus and bubaline coronavirus. Even though humans are the predominant contributors to wastewater, studies have shown that other organisms including: dogs, birds, cows, and pigs, also contribute to a lesser extent [40,41]. To further investigate the origin/source of in situ detections, the BCoV primers underwent a BLAST query and were assessed using Geneious Prime 2025.1.3 software. Although the resulting output revealed several candidate organisms (Table S1) that theoretically could cause the cross-reactivity, in practice this seems unlikely given that many of them are not native to the collection site. Additionally, many of these potential genetic targets were not a 100% match to primer and probe sequences (Table S1; Figure S1), minimizing the chances of cross-reactivity in wastewater due to reduced sensitivity. In addition, all the BCoV signals obtained from this experiment fell below the reported limit of detection of 20 copies per reaction [33] and would likely have a negligible effect on extraction efficiency measures. With consideration of these observations, we believe that BCoV is still an appropriate process control for use in wastewater extraction efficiency measures, though laboratories should test for in situ BCoV before employing its use. Lastly, we assessed the probability of the BCoV vaccine inducing false-positives in other qPCR assays used to detect commonly-monitored pathogens in wastewater. As our standard protocol uses 5 µL of BCoV vaccine per wastewater spike, we tested concentrations beyond our standard extraction to assess the degree of potential cross-reaction. The BCoV vaccine was directly extracted using the MP96 at 4X (20 µL BCoV and 180 µL 1X TE buffer) and 40X (200 µL BCoV) volumes. No cross-reaction was observed in any of our in-use assays in either condition (Table S2). Therefore, there is negligible risk of introducing false-positive signal with any of our existing assays. Determination of extraction efficiencies and the effects of BCoV incubation times Nucleic acids were extracted using a solids-based wastewater extraction method (as described in the method details section titled “Nucleic acid extraction from solids-fraction of wastewater”). To facilitate this process and optimize laboratory resources, 30 mL wastewater aliquots are prepared a day prior to extraction. For this purpose, an assessment of not only the extraction efficiency, but also the impacts of BCoV incubation times in wastewater, was necessary. Also, other studies have shown that viral partitioning is an important consideration when conducting WBS [6,42,43]. Given that this method explores the extraction efficiency of the solids partition of wastewater, an investigation into the effects of incubation on spiked BCoV was pertinent. This began by preparing 700 mL pools of wastewater each from WWTP/site 1, 2, and 3. These pools were further split into six treatment streams that were spiked with 5 µL of BCoV at various points in the extraction process (Fig. 3). The spike was added to four 30 mL wastewater aliquots and divided into incubation groups at 4 °C, which included: 30 min, 16 h, 40 h, and 64 h. Additionally, the BCoV vaccine was added at the bead-beating step and spiked into the bead-beating tube with the wastewater pellet. Finally, the BCoV vaccine was added at the purification step and directly spiked into the wastewater lysate in the MP96 extraction cartridge. BCoV concentration was measured in all of the wastewater extracts and recovery was assessed by comparing to the seeded baseline concentration of the BCoV vaccine. Illustration of experiment design for measuring the effects of bovine coronavirus (BCoV) incubation times on wastewater extraction efficiencies. Created in BioRender. Mejia, E. (2026)https://BioRender.com/bihtftm. Within the aggregated sites data, our results show that the 30 min incubation has significantly lower recovery compared to 16 h (Fig. 4A), with mean BCoV percent recoveries of 1.64% and 3.57%, respectively. In addition, across all three sites, the incubation data shows a non-significant decreasing trend in BCoV percent recovery from 16 to 64 h, providing some insight into the stability of the BCoV vaccine in wastewater (Fig. 4B). No consistent significant differences were observed between 30 min and 64 h. It is possible that the 30 min of incubation is not sufficient for the BCoV to bind to the solid material present in wastewater. On the other end, incubations longer than 64 h may result in greater viral degradation compared to shorter times. Studies describing decay kinetics of BCoV in wastewater are limited, and this study did not perform measurements beyond 64 h of incubation. Most protocols are not prescriptive regarding BCoV incubation times [3] resulting in wide variations in existing literature ranging from immediate processing to seven days [11,44,45]. Likewise, BCoV extraction efficiencies reported by other laboratories range from as low as 0.08% to as high as 30% [31,46,47]. Differences in extraction protocols will undoubtedly impact surrogate virus recovery, which is why obtained extraction efficiencies and incubation times should be carefully evaluated by laboratories conducting WBS. The relationship between bovine coronavirus (BCoV) incubation times and percent recovery in BCoV-spiked wastewater. BCoV recovery is calculated as the wastewater extract BCoV quantification (singleplex RT-qPCR) divided by the BCoV vaccine heat lysis quantification (RT-dPCR). (A) Aggregate results for BCoV percent recovery from all three wastewater sites in biological triplicate (n = 9). (B) BCoV percent recovery of the individual wastewater sites in biological triplicate (n = 3). Significant differences are indicated by *p<0.05,**p<0.01,***p<0.001,****p<0.0001 (Dunn test with Holm correction). Non-significant differences are omitted. Despite an observed decreasing trend in BCoV percent recovery from 16 to 64 h from both the site-specific and aggregated results, the data did not reach significance. Only the 30 min incubation time showed significantly lower percent recovery compared to other time points (p < 0.001 vs 16 h, p = 0.008 vs 40 h; Dunn post-hoc test with Holm correction). Therefore, incubation times shorter than 16 h are not recommend for BCoV in wastewater. We highly recommend extraction efficiency trends are monitored longitudinally for all in-scope sites to detect any deviations from the expected recovery. To establish a percent recovery baseline, we recommend that 20 samples be tested for each site to stabilize variability and minimize the calculated standard deviation. Provided that a stable baseline is established when this protocol is on-boarded by laboratories, the focus should not solely lie on the level of the percent recovery, but also on its stability over time. This could be accomplished using statistical QC methods like the Levey-Jennings analysis and monitoring for percent extraction efficiency changes that exceed two standard deviations, for example. This longitudinal measurement of BCoV could also help with any potential BCoV signals detected as a result of its endogenous presence, as discussed in the “BCoV background in wastewater” section. Outlier thresholds will need to be determined empirically by laboratories, but it is recommended that at a minimum, once an outlier is identified based on Levey-Jennings set parameters, that sample should be re-tested to confirm the results. If results are confirmed, the endogenous BCoV viral load should be subtracted from the spiked amount to more accurately assess extraction efficiency. This validation also included a comparison of the extraction efficiencies between positive controls and wastewater samples (Fig. 5). To this end, 5 µL of BCoV vaccine was spiked into the following test groups: MP96 cartridge containing 1X TE buffer, bead-beating tube containing 1X TE buffer, MP96 cartridge containing wastewater sample, and bead-beating tube containing wastewater sample. The results of these test conditions were compared to the aggregated wastewater samples spiked with BCoV and incubated for 16–64 h at 4 °C. Our results show the recovery of BCoV is significantly higher for the MP96 cartridge containing wastewater sample and bead-beating tube containing wastewater sample positive controls compared to the aggregated wastewater samples (p < 0.001; Dunn post-hoc test with Holm correction). No significant differences were observed between the MP96 cartridge containing 1X TE buffer and bead-beating tube containing 1X TE buffer positive controls and the aggregated wastewater samples. These findings are indicative of the protective effects of solid material on viral particles in wastewater compared to free and suspended virus as well as the demonstrate that signal may be lost due to the incubation step. Studies have previously shown that viral particles and RNA in wastewater, bound to solids, decay slower and are found in greater quantities compared to free and suspended virus [48,49]. However, this effect may only be partially effective for the spiked BCoV, which is a limitation of its use. These findings also highlight key differences that can be found in extraction efficiency measures depending on where in the extraction process BCoV is spiked, and should be considered by laboratories performing WBS. In fact, these spike-in sites can be used as a guide to help identify if any changes to this protocol improve extraction efficiencies. Measuring the percent recovery of bovine coronavirus (BCoV) spiked-in at control steps in the solids-based wastewater extraction protocol which include: the MP96 cartridge and bead-beating tube. These results were compared to the percent recovery from wastewater samples spiked with BCoV and incubated for 16–64 h. BCoV recovery is calculated as the wastewater extract BCoV quantification (Singleplex RT-qPCR) divided by the BCoV vaccine heat lysis quantification (RT-dPCR). Significant differences are indicated by *p<0.05,**p<0.01,***p<0.001,****p<0.0001 (Dunn test with Holm correction). Non-significant differences are omitted. PMMoV and BCoV qPCR duplex assay validation The BCoV qPCR test from Decaro et al. [33] was incorporated into a duplex RT-qPCR assay with PMMoV [32] to allow for efficient use of both samples and reagents. To assess assay performance following conversion to multiplex, five-point standard curves were prepared from both BCoV and PMMoV gBlocks as described in Table 8, and generated using both the singleplex and duplex assays and pooled and unpooled controls at equimolar concentrations (Fig. 6). Analysis of covariance (ANCOVA) was employed to measure statistical slope and intercept differences arising from duplexing (Fig. 6A) and/or template pooling (Fig. 6B). Results show minimal insignificant differences in slopes for all conditions (slope differences ≤ 0.05, p > 0.1), with the exception of BCoV standard curves using unpooled gBlocks (slope difference = 0.05, p = 0.02). Although statistically significant, the 0.05 difference in slope is biologically negligible and passes MIQE guidelines [35]. The observed differences are likely driven by the greater precision of the PCR reaction with unpooled template. Similarly, statistically significant differences were also observed between BCoV and PMMoV y-intercepts when comparing singleplex and duplex reactions (BCoV y-intercept differences = 0.38 and 0.28, p < 0.01; PMMoV y-intercept differences = −0.70 and −0.42, p < 0.01) that would have negligible effects on quantification since there is no loss in sensitivity and the change is consistent. Interestingly, no significant differences were detected when comparing the effects of pooling templates. The effect of (A) multiplexing and (B) positive control pooling on the linear standard curves of bovine coronavirus (BCoV) and pepper mild mottle virus (PMMoV) qPCR assays. Full standard curve parameters can be found in Table S3. Significant differences are indicated by *p<0.05,**p<0.01,***p<0.001,****p<0.0001,n.s.=notsignificant (ANCOVA). Next, we sought to validate the performance of this duplex assay using wastewater by comparing the detections of the duplex and singleplex versions in BCoV-spiked samples from six WWTPs. For PMMoV, 20 BCoV-spiked samples from each of the six sites were used to compare the duplex and singleplex versions (Fig. 7A, B). Using a linear correlation analysis, our results show excellent positive correlation (R2 = 0.9116) between duplex and singleplex versions of the test. These results also show a moderate tendency for the singleplex version of the PMMoV assay to quantify higher compared to the duplex (as shown by the slope = 0.6), however, this effect is largely driven by site 2A which typically exhibits higher PMMoV concentrations than the rest of the sites. When conducting the linear correlation analysis using the 1:10 diluted nucleic acid/template, excellent positive correlation is still observed (R2 = 0.8913) and is coupled with an increase in the slope to 0.8, which indicates greater similarity between duplex and singleplex quantifications. The greater PMMoV levels routinely detected in site 2A and the outlier detections from sites 1A and 3B are indicative of wastewater samples with greater fecal loads, which may contain greater accompanying inhibitors [50,51]. For this reason, it is recommended that when using the PMMoV and BCoV duplex assay, the 1:10 PMMoV concentration is longitudinally monitored for QA/QC purposes while still using the neat concentration for inhibition calculation (ΔCt). Linear regressions comparing the concentration measured using singleplex and duplex pepper mild mottle virus (PMMoV) and bovine coronavirus (BCoV) RT-qPCR assays. Wastewater samples were tested for endogenous PMMoV and exogenous BCoV. (A) Singleplex versus duplex PMMoV quantification of neat wastewater nucleic acids (n = 120). (B) Singleplex versus duplex PMMoV quantification of 1:10 diluted wastewater nucleic acids (n = 120). (C) Singleplex versus duplex BCoV quantification of neat wastewater nucleic acids (n = 13). (D) Singleplex versus duplex BCoV quantification of 1:10 diluted wastewater nucleic acids (n = 13). For the validation of the BCoV portion of the duplex assay, 13 samples from six WWTPs were used to compare duplex to singleplex performance. This was done as a preliminary assessment of the assay to capture any potential differences between duplex and singleplex versions, hence the use of fewer samples compared to the PMMoV validation. Our results (Fig. 7C, D) show that excellent positive correlation exists between the BCoV duplex and singleplex versions for both neat and the 1:10 dilution (R2 = 0.8353 and 0.9595, respectively). Next, we used 19–21 BCoV-spiked wastewater samples (variability is a result of sample availability) from each of the six WWTPs and measured the BCoV extraction efficiency over a ten week period (Fig. 8). Also, nucleic acid sample extracts were compared at both neat and a 1:10 dilution for each site during this same time period. Lastly, all of these samples were additionally tested for in situ BCoV (Table S4). Results show that extraction efficiencies are largely consistent within each site, with only a few exceptions in which spikes were detected (Fig. 8). Interestingly, out of a total of 120 samples tested, only two were positive for in situ BCoV (Table S4). The two in situ BCoV signals detected are 10,000X and 1,000X (respectively) smaller compared to both the spike-in concentration and lower range recovered concentration (i.e. maximum in situ BCoV = 3 cp/mL WW; expected spiked BCoV = 3 × 105 cp/mL equivalent; minimum recovered BCoV = 3 × 105 cp/mL equivalent). In addition, both of those positive samples originated from site 3B and do not align with any observable spikes in extraction efficiencies. These findings show that although in situ BCoV is rare and lowly abundant, samples should be carefully monitored to ensure that any changes in extraction efficiency are properly interpreted. Our results also show that when comparing the extraction efficiencies of neat and 1:10 diluted template (Fig. 8), five out of six sites show a significantly greater value with the 1:10 dilution (paired t-tests). However, though statistically significant, the difference in median extraction efficiency between neat and 1:10 diluted template for sites 3A and 3B is 0.4% and 0.3%, respectively. Additionally, there was no significant difference between neat and 1:10 extraction efficiencies in site 9. These findings show that site-to-site variations may occur that could impact the performance of the BCoV and PMMoV duplex assay. Therefore, it is highly recommended that BCoV extraction efficiency is longitudinally monitored using both the neat and 1:10 diluted template to better capture existing WWTP diversity. Longitudinal extraction efficiency (equation 4) of a solids-based wastewater extraction using bovine coronavirus-spiked (BCoV) wastewater (spiked at 7.3 × 106 cp/extraction) and quantified with the BCoV portion of the PMMoV-BCoV duplex RT-qPCR assay (n = 19–21 per site). The site variability is indicated with a boxplot summarizing the neat and 1:10 diluted quantifications. Significant differences between neat and 1:10 diluted nucleic acids are indicated by *p<0.05,**p<0.01,***p<0.001,****p<0.0001,n.s.=notsignificant (paired t-test). Overall, our results show that combining BCoV and PMMoV RT-qPCR assays into a duplex reaction does not meaningfully impact the performance of the tests and allows for the efficient measure of both targets. Limitations The method outlined here, though promising and in alignment with previous studies, has limitations that must be considered. First, this method describes the extraction of nucleic acids from wastewater using a solids-based protocol. A wide variety of wastewater extraction methods have been developed and optimized for the monitoring of SARS-CoV-2 [52], and it is possible that the findings reported here may differ if applied to alternative protocols. Also, only BCoV was used in the validation protocol, and it is possible that other surrogates may yield different results. In addition, although efforts were made to account for BCoV incubation times when samples arrived at the laboratory, its on-site inclusion at time of wastewater collection was not examined. However, despite these limitations, the findings of this work provide novel insights into the use of BCoV to measure extraction efficiencies and its use in a WBS QA/QC system. CRediT author statement Codey E. Dueck: Conceptualization, Writing – original draft, Writing – review & editing, Methodology, Formal analysis, Investigation, Data curation, Visualization. Nataliya Santiago: Writing – original draft, Writing – review & editing, Formal analysis, Data curation, Visualization. Nikho A. Hizon: Conceptualization, Writing – review & editing. Ravinder Lidder: Conceptualization, Writing – review & editing. Dave Spreitzer: Investigation. Umar P. Mohammed: Investigation. MacKenzie Dyck: Investigation. Chand S. Mangat: Conceptualization, Writing – review & editing. Edgard M. Mejia: Conceptualization, Writing – original draft, Writing – review & editing, Methodology, Validation, Supervision. Ethics statements Not applicable. Declaration of interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgments We thank and acknowledge the continued contributions of all participating sites and wastewater treatment plant operators who made this work possible. We also acknowledge the support from Statistics Canada in helping us collect the wastewater samples used to develop this method. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Footnotes Related research article: None For a published article: None Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.mex.2026.104059. Supplementary materials Data availability Data will be made available on request. References Associated Data Supplementary Materials Data Availability Statement Data will be made available on request.